Reply to K. Takada et al [0.03%]
答小田克也等人的论文
Madison Ballman,Cristina Mullenix,Eva Szabo et al.
Madison Ballman et al.
Response to Icotinib Plus Chemotherapy in Pulmonary Atypical Carcinoid Harboring the EGFR L858R Mutation: A Brief Report [0.03%]
伊科替尼联合化疗治疗肺类癌EGFR L858R突变阳性一例报告
Yu-Qing Chen,Yu-Fa Li,Chan-Yuan Zhang et al.
Yu-Qing Chen et al.
Introduction: Pulmonary atypical carcinoid (PAC) is a rare subtype of pulmonary neuroendocrine neoplasm. Although EML4-ALK fusion has been detected in PAC, EGFR mutations have not been reported before. ...
Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy [0.03%]
老年无法手术的III期NSCLC患者的同期放化疗联合或不联合度伐利尤单抗的疗效和安全性
Sally C M Lau,Malcolm Ryan,Jessica Weiss et al.
Sally C M Lau et al.
Introduction: The addition of durvalumab after chemoradiation therapy (CRT) in unresectable stage III NSCLC significantly improves survival. The benefit of this approach in elderly patients is controversial given the toxi...
Surgical Insights Are Essential to Integration of Immune Therapy in Resectable NSCLC [0.03%]
外科视角对于可手术NSCLC的免疫治疗整合至关重要
Jessica S Donington
Jessica S Donington
Discrimination Between Primary Lung Cancer and Lung Metastases by Genomic Profiling [0.03%]
通过基因组分析区分原发性肺癌和肺转移癌
Rumi Higuchi,Taichiro Goto,Takahiro Nakagomi et al.
Rumi Higuchi et al.
Introduction: In cases of lung tumors that occur after treatment for malignancies in other organs, the tumor may represent either a primary lung cancer or a solitary pulmonary metastasis from the other tumor. Because some...
Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC [0.03%]
他汀类药物使用与早期非小细胞肺癌复发风险降低在肥胖人群中的关联性研究
Santosh K Patnaik,Cara Petrucci,Joseph Barbi et al.
Santosh K Patnaik et al.
Introduction: Statins, used for their lipid-lowering activity, have anti-inflammatory and anticancer properties as well. We evaluated this potential benefit of statin use in patients with NSCLC. ...
A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada [0.03%]
在加拿大广泛期小细胞肺癌患者中对atezolizumab联合铂类-etoposide化疗进行真实世界评估
Anifat A Elegbede,Amanda J Gibson,Andrea S Fung et al.
Anifat A Elegbede et al.
Introduction: The real-world data evaluating treatment outcomes of atezolizumab plus carboplatin-etoposide chemotherapy (atezolizumab) for extensive-stage SCLC (ESCLC) are lacking. Our objective was to evaluate real-world...
Early Response to Chemotherapy in Malignant Pleural Mesothelioma Evaluated Using Diffusion-Weighted Magnetic Resonance Imaging: Initial Observations [0.03%]
弥散加权磁共振成像评估恶性胸膜间皮瘤对化疗早期反应的初步观察
Sebastian Curcean,Lin Cheng,Simona Picchia et al.
Sebastian Curcean et al.
Introduction: We compared the magnetic resonance imaging total tumor volume (TTV) and median apparent diffusion coefficient (ADC) of malignant pleural mesothelioma (MPM) before and at 4 weeks after chemotherapy, to evalua...
Correspondence Regarding "Tolerability of Coronavirus Disease 2019 Vaccines BNT162b2 and mRNA-1273 in Patients With Thymic Epithelial Tumors" [0.03%]
关于"新型冠状病毒疾病2019疫苗BNT162b2和mRNA-1273在胸腺上皮肿瘤患者中耐受性"的来信讨论
Kazuki Takada,Shinkichi Takamori,Naoko Miura et al.
Kazuki Takada et al.
Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC [0.03%]
NSCLC中获得性EGFR酪氨酸激酶抑制剂耐药机制分子分析的现实世界方法
Liesbeth M Hondelink,Merel Jebbink,Jan H von der Thüsen et al.
Liesbeth M Hondelink et al.
Introduction: With the approval of first-line osimertinib treatment in stage IV EGFR-mutated NSCLC, detection of resistance mechanisms will become increasingly important-and complex. Clear guidelines for analyses of these...